Table 2.
Sensitivity and specificity of the examined SARS-CoV-2 assays.
| Assay | SARS-CoV-2 antigen (recombinant) | Sensitivity (%) | Specificity (%) | Specificity (%) incl. SARS-CoV (2003)** |
|---|---|---|---|---|
| SARS-CoV-2-IgG (Abbott) | N protein | 77.8 (35/45) | 100 (35/35) | 94.6 (35/37) |
| Elecsys Anti-SARS-CoV-2* | N protein | 75.6 (34/45) | 97 (33/34) | 91.7 (33/36) |
| Liaison® SARS-CoV-2 S1/S2 IgG | S1 and S2 protein | 75.6 (34/45) | 100 (35/35) | 94.6 (35/37) |
| COVID-19 VIRCLIA® IgG MONOTEST | S1 and N protein | 89 (40/45) | 100 (31/31) | 93.9 (31/33) |
| Anti-SARS-CoV-2-ELISA (IgG) (Euroimmun) | S1 protein | 71.1 (32/45) | 100 (20*/20) | 100 (22/22) |
| Virotech SARS-CoV-2 ELISA IgG | N protein | 66.7 (30/45) | 100 (35/35) | 94.6 (35/37) |
| PRNT (in-house developed) | whole virus | 93.3 (42/45) | 97.1 (34/35)*** | 94.6 (35/37)**** |
*
two equivocal results (HCoV-OC43, negative control cohort) were considered as negative.
**
including follow up samples of SARS-CoV (2003 outbreak), which is closely related to SARS-CoV-2.
***
three equivocal results (one HCoV-229E sample, two in the negative control cohort were considered negative).
****
one equivocal result for one SARS-CoV sample was considered negative.